Terns Pharmaceuticals, Inc. – TERN-701 Investor Educational Webinar Transcript

Operator

Good day, and thank you for standing by. Welcome to the TERN-701 Investor and Educational Webinar. [Operator Instructions]. Please be advised that today’s conference is being recorded and that slides available on today’s webinar need to be self advanced by the viewer. [Operator Instructions]. I would now like to hand the conference over to your speaker today, Amy Burroughs, Chief Executive Officer.

Amy Burroughs
CEO & Director

Good afternoon, everyone. I’m Amy Burroughs, Chief Executive Officer of Terns Pharmaceuticals. On behalf of the Terns team, I thank you for joining us today for our educational webinar on TERN-701, our investigational next-generation oral Allosteric BCR-ABL inhibitor that is being evaluated for the treatment of chronic myeloid leukemia or CML. Today, we will touch upon TERN-701’s potential best-in-class profile, relevant benchmarks for assessing our upcoming Phase I data expected next quarter and potential position of TERN-701 and an evolving treatment landscape for CML.

Before we begin, let me draw your attention to the fact that throughout the course of today’s program, we will be making forward-looking statements. I invite you to our SEC quarterly and annual filings to review our forward-looking statements, disclaimers and important risk factors. Finally, please note this webinar event is for informational and educational purposes only and is not intended for the media. So let’s begin on Page 3. We’re excited to focus today’s discussion